MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592904 | Name: Apaflurane

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Apaflurane is a biochemical.

Chemical Structure

Apaflurane
Apaflurane
CAS#431-89-0

Theoretical Analysis

MedKoo Cat#: 592904

Name: Apaflurane

CAS#: 431-89-0

Chemical Formula: C3HF7

Exact Mass: 169.9966

Molecular Weight: 170.03

Elemental Analysis: C, 21.19; H, 0.59; F, 78.21

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Apaflurane; FM 200; FM-200; FM200
IUPAC/Chemical Name
1,1,1,2,3,3,3-Heptafluoropropane
InChi Key
YFMFNYKEUDLDTL-UHFFFAOYSA-N
InChi Code
InChI=1S/C3HF7/c4-1(2(5,6)7)3(8,9)10/h1H
SMILES Code
C(C(F)(F)F)(C(F)(F)F)F
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 170.03 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Köster U, Mayer D, Deger HM, DeKant W. Biotransformation of the aerosol propellant 1,1,1,2,3,3,3-heptafluoropropane (HFA-227): lack of protein binding of the metabolite hexafluoroacetone. Drug Metab Dispos. 1996 Aug;24(8):906-10. PubMed PMID: 8869827. 2: Emmen HH, Hoogendijk EM, Klöpping-Ketelaars WA, Muijser H, Duistermaat E, Ravensberg JC, Alexander DJ, Borkhataria D, Rusch GM, Schmit B. Human safety and pharmacokinetics of the CFC alternative propellants HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3, 3-heptafluoropropane) following whole-body exposure. Regul Toxicol Pharmacol. 2000 Aug;32(1):22-35. PubMed PMID: 11029265. 3: Sheth P, Stein SW, Myrdal PB. The influence of initial atomized droplet size on residual particle size from pressurized metered dose inhalers. Int J Pharm. 2013 Oct 15;455(1-2):57-65. doi: 10.1016/j.ijpharm.2013.07.061. Epub 2013 Aug 1. PubMed PMID: 23911912. 4: Lee EPF, Dyke JM, Chow WK, Chau FT, Mok DKW. DFT and ab initio calculations on two reactions between hydrogen atoms and the fire suppressants 2-H heptafluoropropane and CF3Br. J Comput Chem. 2007 Jul 15;28(9):1582-1592. doi: 10.1002/jcc.20695. PubMed PMID: 17340604. 5: Reid ML, Benaouda F, Khengar R, Jones SA, Brown MB. Topical corticosteroid delivery into human skin using hydrofluoroalkane metered dose aerosol sprays. Int J Pharm. 2013 Aug 16;452(1-2):157-65. doi: 10.1016/j.ijpharm.2013.04.083. Epub 2013 May 14. PubMed PMID: 23684656. 6: Alexander DJ, Libretto SE, Adams MJ, Hughes EW, Bannerman M. HFA-134a (1,1,1,2-tetrafluoroethane): effects of inhalation exposure upon reproductive performance, development and maturation of rats. Hum Exp Toxicol. 1996 Jun;15(6):508-17. PubMed PMID: 8793535. 7: Cooper KM, Chang SF, Harrison LI. Determination of the chlorofluorocarbon substitute 1,1,1,2-tetrafluoroethane (HFA-134a) in human and animal blood using gas chromatography with headspace analysis. J Chromatogr B Biomed Appl. 1995 May 5;667(1):85-93. PubMed PMID: 7663689. 8: Vinegar A, Jepson GW, Cisneros M, Rubenstein R, Brock WJ. Setting safe acute exposure limits for halon replacement chemicals using physiologically based pharmacokinetic modeling. Inhal Toxicol. 2000 Aug;12(8):751-63. PubMed PMID: 10880155. 9: Aubier M, Wettenger R, Gans SJ. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(-1)) versus HFA-fluticasone propionate (1000 microg day(-1)) in patients with asthma. Respir Med. 2001 Mar;95(3):212-20. PubMed PMID: 11266239. 10: Corda L, Gardenghi GG, Modina D, Montemurro LT, Novali M, Tantucci C. Effects on small airway obstruction of long-term treatments with beclomethasone/formoterol hydrofluoroalkane (metered-dose inhaler) versus fluticasone/salmeterol (dry-powder inhaler) in asthma: a preliminary study. Allergy Asthma Proc. 2011 Nov-Dec;32(6):29-34. doi: 10.2500/aap.2011.32.3477. PubMed PMID: 22221427. 11: Hirst PH, Pitcairn GR, Weers JG, Tarara TE, Clark AR, Dellamary LA, Hall G, Shorr J, Newman SP. In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler. Pharm Res. 2002 Mar;19(3):258-64. PubMed PMID: 11934231. 12: Fowler SJ, Orr LC, Sims EJ, Wilson AM, Currie GP, McFarlane L, Lipworth BJ. Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate. Chest. 2002 Aug;122(2):618-23. PubMed PMID: 12171841. 13: Proquitté H, Kusztrich A, Auwärter V, Pragst F, Wauer RR, Schmalisch G. Functional residual capacity measurement by heptafluoropropane in ventilated newborn lungs: in vitro and in vivo validation. Crit Care Med. 2006 Jun;34(6):1789-95. PubMed PMID: 16625130. 14: Dubus JC, Montharu J, Vecellio L, De Monte M, De Muret A, Goucher A, Cantagrel S, Le Pape A, Mezzi K, Majoral C, Le Guellec S, Diot P. Lung deposition of HFA beclomethasone dipropionate in an animal model of bronchopulmonary dysplasia. Pediatr Res. 2007 Jan;61(1):21-5. PubMed PMID: 17211135. 15: Ratner P, Jacobs R, Mohar D, Huang H, Desai SY, Hinkle J. Evaluation of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol, 80 or 160 μg once daily, for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2010 Dec;105(6):471-9. doi: 10.1016/j.anai.2010.09.024. PubMed PMID: 21130386. 16: Wu L, da Rocha SR. Biocompatible and biodegradable copolymer stabilizers for hydrofluoroalkane dispersions: a colloidal probe microscopy investigation. Langmuir. 2007 Nov 20;23(24):12104-10. Epub 2007 Oct 25. PubMed PMID: 17958454. 17: Derom E, Pauwels RA. Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. Clin Pharmacokinet. 2005;44(8):815-36. Review. PubMed PMID: 16029067. 18: Nelson HS, Kane RE, Petillo J, Banerji D. Long-term safety of a non-chlorofluorocarbon-containing triamcinolone acetonide inhalation aerosol in patients with asthma. Azmacort HFA Study Group. J Asthma. 2000 Apr;37(2):145-52. PubMed PMID: 10805203. 19: Nolting A, Sista S, Abramowitz W. Single-dose study to compare the pharmacokinetics of HFA flunisolide and CFC flunisolide. J Pharm Sci. 2002 Feb;91(2):424-32. PubMed PMID: 11835202. 20: Currie GP, Fowler SJ, Wilson AM, Sims EJ, Orr LC, Lipworth BJ. Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma. Thorax. 2002 Oct;57(10):865-8. PubMed PMID: 12324672; PubMed Central PMCID: PMC1746197.